Publications by authors named "Nozomi Nishitarumizu"
Article Synopsis
- Anti-CD38 monoclonal antibodies improve outcomes for patients with plasma cell dyscrasia (PCD) but increase the risk of infections like cytomegalovirus (CMV) reactivation.
- A retrospective study involving 154 PCD patients found that 38% of those tested for CMV reactivation showed positive results, with some experiencing mild symptoms and others developing serious conditions.
- The reactivation of CMV significantly impacted treatment by causing dose adjustments and delays in anti-PCD therapies, highlighting the need for monitoring during anti-CD38 mAb treatment.
Article Synopsis
- Researchers studied the immune response in 109 patients with plasma cell dyscrasia (PCD) after receiving two or three doses of the SARS-CoV-2 mRNA vaccine, focusing on the production of antibodies and immune cells.
- The results indicated that while ongoing anti-myeloma treatments negatively affected antibody production, booster dose (Dose 3) significantly improved antibody levels and the number of patients achieving adequate immune response.
- The study underscored the importance of the booster vaccine for enhancing both humoral (antibody) and cellular immune responses in PCD patients, noting specific drug classes that had varying impacts on vaccine effectiveness.
Article Synopsis
- This study evaluated the immune response to SARS-CoV-2 mRNA vaccines in 165 lymphoma patients, focusing on their antibody levels after the second and third doses.
- Results showed that after the second dose, 56% had adequate antibody responses, while 28% were non-responders, influenced by factors like timing of vaccination after chemotherapy and lymphocyte count.
- After the third dose, there was a notable increase in antibody levels, with 26% of previous non-responders achieving seroconversion, indicating that additional vaccine doses can improve immune responses in immunocompromised individuals.